Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
86.45
+7.02 (8.84%)
Nov 20, 2024, 4:00 PM EST - Market closed
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $378.73M in the quarter ending September 30, 2024, with 18.37% growth. This brings the company's revenue in the last twelve months to $1.50B, up 24.15% year-over-year. In the year 2023, Lantheus Holdings had annual revenue of $1.30B with 38.65% growth.
Revenue (ttm)
$1.50B
Revenue Growth
+24.15%
P/S Ratio
3.99
Revenue / Employee
$1,794,723
Employees
834
Market Cap
6.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
Dec 31, 2019 | 347.34M | 3.96M | 1.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Halozyme Therapeutics | 947.36M |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
Corcept Therapeutics | 628.56M |
Blueprint Medicines | 434.42M |
Krystal Biotech | 241.52M |
Avidity Biosciences | 10.12M |
LNTH News
- 1 day ago - Lantheus Announces Share Repurchase Program - GlobeNewsWire
- 7 days ago - Lantheus to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 10 days ago - Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025 - GlobeNewsWire
- 12 days ago - Lantheus Holdings: Q3 Results Were Good But Market Overreacted - Seeking Alpha
- 14 days ago - Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care - GlobeNewsWire
- 4 weeks ago - Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time - GlobeNewsWire
- 2 months ago - Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 - GlobeNewsWire